Abstract
Purpose
The monoclonal antibody pertuzumab represents the first HER2 dimerization inhibitor with unknown activity in colon cancer treatment. We examined the antitumor activity of pertuzumab as a single agent or in combination with erlotinib or irinotecan in human colon cancer cells in vitro and in vivo.
Methods
Colon cancer cell lines were tested for HER1/HER2 expression by western blot analysis. The effect of pertuzumab on cell cycle distribution was analyzed by FACS. Nude mice bearing xenograft tumors were treated with pertuzumab alone, or in combination either with irinotecan or with erlotinib. Tumor volume was measured repeatedly. Tumor histology was analyzed for necrosis.
Results
Six of nine cell lines showed high expression of HER1/HER2. Pertuzumab inhibited cell cycle progression in various cell lines. Pertuzumab showed minor antitumor activity in xenograft tumors, but significantly inhibited tumor growth when combined with erlotinib (P < 0.001). Combination of pertuzumab with irinotecan had no additional effect on growth of additional tumors. Pertuzumab treated DLD-1 xenograft tumors did not show enhanced necrosis, which, however, was found in HCT116 derived xenografts.
Conclusions
Pertuzumab has some antitumor activity on human colon cancer cells in vitro and in vivo, in particular when combined with erlotinib. In vivo, pertuzumab combination treatment was not superior to irinotecan monotherapy. These data warrant further investigation of simultaneous HER1/EGFR TKI inhibition and HER1/HER2 dimerization inhibition for colorectal cancer therapy.
Similar content being viewed by others
Abbreviations
- HER:
-
Human epidermal growth factor receptor
- EGFR:
-
Epidermal growth factor receptor
- MAPK:
-
Mitogen-activated protein kinase
- TKI:
-
Tyrosine kinase inhibitor
References
Adams CW, Allison DE, Flagella K et al (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717–727. doi:10.1007/s00262-005-0058-x
Agus DB, Akita RW, Fox WD, Lewis GD (2002) Targeting ligand-activated ErbB-2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127–137. doi:10.1016/S1535-6108(02)00097-1
Agus DB, Gordon MS, Taylor C et al (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534–2542. doi:10.1200/JCO.2005.03.184
Akita RW, Sliwkowski MX (2003) Preclinical studies with erlotinib (Tarceva). Semin Oncol 30:15–24
Arpino G, Gutierrez C, Weiss H et al (2007) Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99:694–705. doi:10.1093/jnci/djk151
Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23:2445–2459. doi:10.1200/JCO.2005.11.890
Black JD, Brattain MG, Krishnamurthi SA, Dawson DM, Willson JK (2003) ErbB family targeting. Curr Opin Investig Drugs 4:1451–1454
Carpenter G, Cohen S (1990) Epidermal growth factor. J Biol Chem 265:7709–7712
Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648
Dursun A, Poyraz A, Suer O, Sezer C, Akyol G (2001) Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol Oncol Res 7:24–27
Ferlay J, Bray F, Pisani P et al (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC cancerbase no. 5. IARC, Lyon, France
Fields LA, Rinaldi D, Henderson CA et al (2005) An open-label multicenter phase II study of oral Lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 23:3583
Franklin MC, Carey KD, Vajdos FF, Leahy DJ, deVos AM, Sliwkowski MX (2004) Insights into ErbB signaling from the structure of the ErbB-2-pertuzumab complex. Cancer Cell 5:317–328. doi:10.1016/S1535-6108(04)00083-2
Friess T, Bauer S, Burger AM (2002) In vivo activity of recombinant humanized monoclonal antibody 2C4 in xenografts is independent of tumor type and degree of HER-2 overexpression. Eur J Cancer 38:149–156
Friess T, Scheuer W, Hasmann M (2005) Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 11:5300–5309. doi:10.1158/1078-0432.CCR-04-2642
Grunwald V, Hidalgo M (2003) Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). Adv Exp Med Biol 532:235–246
Hemming AW, Davis NL, Kluftinger A et al (1992) Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 51:147–152. doi:10.1002/jso.2930510304
Hu YP, Venkateswarlu S, Sergina N et al (2005) Reorganization of ErbB family and cell survival signalling following knockdown of ErbB-2 in colon cancer cells. J Biol Chem 280:27383–27392. doi:10.1074/jbc.M414238200
Jackson JG, St. Clair P, Sliwkowski MX, Brattain MG (2004) Blockage of epidermal growth factor- or heregulin-dependent ErbB-2 activation with the anti-ErbB-2 monoclonal antibody 2C4 has divergent downstream signalling and growth effects. Cancer Res 64:2601–2609. doi:10.1158/0008-5472.CAN-03-3106
Johnson JR, Cohen M, Sridhara R et al (2005) Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11:6414–6421. doi:10.1158/1078-0432.CCR-05-0790
Kapitanovic S, Spaventi R, Poljak L et al (1994) High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters. Cancer Detect Prev 18:97–101
Kapitanovic S, Radosevic S, Kapitanovic M et al (1997) The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112:1103–1113. doi:10.1016/S0016-5085(97)70120-3
Kuwada SK, Scaife CL, Kuang J et al (2004) Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int J Cancer 109:291–301. doi:10.1002/ijc.11686
Learn PA, Krishnegowda N, Talamantez J, Kahlenberg MS (2006) Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines. J Surg Res 136:227–231. doi:10.1016/j.jss.2006.07.046
Mann M, Sheng H, Shao J et al (2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120:1713–1719. doi:10.1053/gast.2001.24844
Mayer A, Takimoto M, Fritz E et al (1993) The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454–2460. doi:10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2
Mendelsohn J (2002) Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1S–13S
Meyerhardt JA, Zhu AX, Enzinger PC et al (2006) Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 24:1892–1897. doi:10.1200/JCO.2005.05.3728
Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966. doi:10.1200/JCO.2006.07.9525
Normanno N, Bianco C, De Luca A et al (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10:1–21. doi:10.1677/erc.0.0100001
Pérez-Soler R, Chachoua A, Hammond LA et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238–3247. doi:10.1200/JCO.2004.11.057
Pollack VA, Savage DM, Baker DA et al (1999) Inhibition of epidermal growth factor receptorassociated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291:739–748
Porebska I, Harlozinska A, Bojarowski T (2000) Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 21:105–115. doi:10.1159/000030116
Prewett MC, Hooper AT, Bassi R et al (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8:994–1003
Ramanathan RK, Hwang JJ, Zamboni WC et al (2004) Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 22:858–865. doi:10.1081/CNV-200039645
Real FX, Rettig WJ, Chesa PG et al (1986) Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 46:4726–4731
Ross JS, McKenna BJ (2001) The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19:554–568. doi:10.1081/CNV-100103852
Saijo N (2000) Preclinical and clinical trials of topoisomerase inhibitors. Ann NY Acad Sci 922:92–99
Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232. doi:10.1016/1040-8428(94)00144-I
Saltz L, Rubin MS, Hochster HS (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:7 Abstract
Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208. doi:10.1200/JCO.2004.10.182
Takai N, Anjali J, Norihiko K et al (2005) 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104:2701–2708. doi:10.1002/cncr.21533
Townsley CA, Major P, Siu LL et al (2006) Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 94:1136–1143. doi:10.1038/sj.bjc.6603055
Zhou Y, Li S, Hu YP et al (2006) Blockade of EGFR and ErbB-2 by the novel dual EGFR and ErbB-2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 66:404–411. doi:10.1158/0008-5472.CAN-05-2506
Acknowledgments
The compounds erlotinib and pertuzumab were supplied by Roche Diagnostics GmbH, Penzberg, Germany. This work was supported by grants from the “Forschungsförderung der Ruhr-Universität” (FoRUM), Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pohl, M., Stricker, I., Schoeneck, A. et al. Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. J Cancer Res Clin Oncol 135, 1377–1386 (2009). https://doi.org/10.1007/s00432-009-0579-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0579-3